J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA could seek misdemeanor charges against J&J officers under the Park Doctrine, which can be invoked against executives who could have prevented adulteration or misbranding of a drug. California Republican Issa says regardless whether criminal indictments come, the case "could be fair warning" to other firms regarding quality system failures.
You may also be interested in...
FDA Resurrects Park Doctrine in Enforcement of Pharmaceutical GMPs
FDA is following through on earlier threats to dust off the long-dormant Park doctrine for holding chief executive officers of pharmaceutical companies personally accountable for manufacturing problems.
FDA Resurrects Park Doctrine in Enforcement of Pharmaceutical GMPs
FDA is following through on earlier threats to dust off the long-dormant Park doctrine for holding chief executive officers of pharmaceutical companies personally accountable for manufacturing problems.
FDA Will Seek More Authority Over Manufacturing In Wake Of J&J Recalls
FDA will monitor more closely manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare